natgillin/translations-raw huggingface dataset:
EU/1/03/258/010 14 tabletter EU/1/03/258/011 28 tabletter EU/1/03/258/012 56 tabletter EU/1/03/258/022 180 tabletter 
EU/1/03/258/010 14 tablets EU/1/03/258/011 28 tablets EU/1/03/258/012 56 tablets EU/1/03/258/022 180 tablets
Forekomsten var hhv. 2,00 % for rosiglitazon over for 1,53 % for komparatorerne [hazard ratio (HR) 1,30 (95 % konfidensinterval (CI) 1,004 - 1,69)]. 
3 In a retrospective analysis of data from 42 pooled short-term clinical studies, the overall incidence of events typically associated with cardiac ischaemia was higher for rosiglitazone containing regimens, 2.00% versus combined active and placebo comparators, 1.53% [hazard ratio (HR) 1.30 (95% confidence interval (CI) 1.004 - 1.69)].
LÆGEMIDLETS NAVN AVANDAMET 2 mg/1000 mg filmovertrukne tabletter 
NAME OF THE MEDICINAL PRODUCT AVANDAMET 2 mg/1000 mg film-coated tablets
Multipakning bestående af 3 pakninger, som hver indeholder 56 filmovertrukne tabletter. 
Multipack comprising 3 packs, each containing 56 film-coated tablets.
Oral tripel-kombinationsbehandling (rosiglitazon, metformin og sulfonylurinstof) (se afsnit 4.4) - Patienter, der hidtil har fået metformin og sulfonylurinstof: Hvor det er hensigtsmæssigt kan AVANDAMET-behandlingen påbegyndes med en dosis af rosiglitazon på 4 mg pr. dag og en dosis metformin, som erstatter den dosis, som allerede indtages. 
- Patients on metformin and sulphonylurea: when appropriate AVANDAMET may be initiated at 4 mg/day rosiglitazone with the dose of metformin substituting that already being taken.
ANGIVELSE AF AKTIVT STOF/AKTIVE STOFFER Hver tablet indeholder 2 mg rosiglitazon (som maleat) og 500 mg metforminhydrochlorid. 
STATEMENT OF ACTIVE SUBSTANCE(S) Each tablet contains 2 mg of rosiglitazone (as maleate) and 500 mg of metformin hydrochloride.
EU/1/03/258/007 14 tabletter EU/1/03/258/008 28 tabletter EU/1/03/258/009 56 tabletter EU/1/03/258/021 180 tabletter 
EU/1/03/258/007 14 tablets EU/1/03/258/008 28 tablets EU/1/03/258/009 56 tablets EU/1/03/258/021 180 tablets
EU/1/03/258/004 28 tabletter EU/1/03/258/005 56 tabletter EU/1/03/258/006 112 tabletter EU/1/03/258/020 360 tabletter 
EU/1/03/258/004 28 tablets EU/1/03/258/005 56 tablets EU/1/03/258/006 112 tablets EU/1/03/258/020 360 tablets
ANGIVELSE AF AKTIVT STOF/AKTIVE STOFFER Hver tablet indeholder 4 mg rosiglitazon (som maleat) og 1000 mg metforminhydrochlorid. 
STATEMENT OF ACTIVE SUBSTANCE(S) Each tablet contains 4 mg of rosiglitazone (as maleate) and 1000 mg of metformin hydrochloride.
- nedsat leverfunktion - akut alkoholforgiftning, alkoholisme (se afsnit 4.4) - diabetisk ketoacidose eller diabetisk prækoma - nyresvigt eller nedsat nyrefunktion f.eks. serumkreatinin niveau > 135 µmol/l hos mænd og 
- hypersensitivity to rosiglitazone, to metformin hydrochloride or to any of the excipients - cardiac failure or history of cardiac failure (New York Heart Association (NYHA) stages I to IV) - an Acute Coronary Syndrome (unstable angina, NSTEMI and STEMI) (see section 4.4) - acute or chronic disease which may cause tissue hypoxia such as: - cardiac or respiratory failure - recent myocardial infarction - shock - hepatic impairment - acute alcohol intoxication, alcoholism (see section 4.4) - diabetic ketoacidosis or diabetic pre-coma - renal failure or renal dysfunction e.g. serum creatinine levels > 135 µmol/l in males and > 110 µmol/l in females and/or creatinine clearance < 70 ml/min (see section 4.4) - acute conditions with the potential to alter renal function such as: - dehydration - severe infection - shock - intravascular administration of iodinated contrast agents (see section 4.4) - lactation.
LÆGEMIDLETS NAVN AVANDAMET 4 mg/1000 mg tabletter rosiglitazon/metformin HCl 
NAME OF THE MEDICINAL PRODUCT AVANDAMET 4 mg/1000 mg tablets rosiglitazone/metformin HCl
Almene symptomer og reaktioner på administrationsstedet Ødem 
General disorders and administration site conditions Oedema
Del af multipakning omfattende 2 pakninger, hver indeholdende 56 filmovertrukne tabletter. 
Component of a multipack comprising 2 packs, each containing 56 film-coated tablets.
EU/1/03/258/001 28 tabletter EU/1/03/258/002 56 tabletter EU/1/03/258/003 112 tabletter EU/1/03/258/019 360 tabletter 
EU/1/03/258/001 28 tablets EU/1/03/258/002 56 tablets EU/1/03/258/003 112 tablets EU/1/03/258/019 360 tablets
LÆGEMIDLETS NAVN AVANDAMET 1 mg/500 mg tabletter rosiglitazon/metformin HCl 
NAME OF THE MEDICINAL PRODUCT AVANDAMET 1 mg/500 mg tablets rosiglitazone/metformin HCl
ANGIVELSE AF AKTIVT STOF/AKTIVE STOFFER Hver tablet indeholder 1 mg rosiglitazon (som maleat) og 500 mg metforminhydrochlorid. 
STATEMENT OF ACTIVE SUBSTANCE(S) Each tablet contains 1 mg of rosiglitazone (as maleate) and 500 mg of metformin hydrochloride.
ANGIVELSE AF AKTIVT STOF/AKTIVE STOFFER Hver tablet indeholder 2 mg rosiglitazon (som maleat) og 1000 mg metforminhydrochlorid. 
STATEMENT OF ACTIVE SUBSTANCE(S) Each tablet contains 2 mg of rosiglitazone (as maleate) and 1000 mg of metformin hydrochloride.
LÆGEMIDLETS NAVN AVANDAMET 2 mg/500 mg tabletter rosiglitazon/metformin HCl 
NAME OF THE MEDICINAL PRODUCT AVANDAMET 2 mg/500 mg tablets rosiglitazone/metformin HCl
LÆGEMIDLETS NAVN AVANDAMET 2 mg/1000 mg tabletter rosiglitazon/metformin HCl 
NAME OF THE MEDICINAL PRODUCT AVANDAMET 2 mg/1000 mg tablets rosiglitazone/metformin HCl
Del af multipakning omfattende 3 pakninger, hver indeholdende 56 filmovertrukne tabletter. 
Component of a multipack comprising 3 packs, each containing 56 film-coated tablets.
KVALITATIV OG KVANTITATIV SAMMENSÆTNING Hver tablet indeholder 1 mg rosiglitazon (som rosiglitazonmaleat) og 500 mg metforminhydrochlorid (svarende til 390 mg fri metforminbase). 
Each tablet contains 1 mg of rosiglitazone (as rosiglitazone maleate) and 500 mg of metformin hydrochloride (corresponding to metformin free base 390 mg).
Hvis du får bivirkninger Tal med lægen eller apoteket, hvis en bivirkning er generende eller bliver værre eller du får 
- If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, tell your doctor or pharmacist.
LÆGEMIDLETS NAVN 
PHARMACEUTICAL FORM
KVALITATIV OG KVANTITATIV SAMMENSÆTNING Hver tablet indeholder 2 mg rosiglitazon (som rosiglitazonmaleat) og 1000 mg metforminhydrochlorid (svarende til 780 mg fri metforminbase). 
Each tablet contains 2 mg of rosiglitazone (as rosiglitazone maleate) and 1000 mg of metformin hydrochloride (corresponding to metformin free base 780 mg).
SU glimepirid* (får i forvejen metformin) 
Sulphonylurea (background metformin) Glimepiride*
Lever og galdeveje Nedsat leverfunktion 
Hepatobiliary disorders liver function disorders
MARKEDSFØRINGSTILLADELSESNUMMER (NUMRE) EU/1/03/258/013, 56 tabletter, del af multipakning med 112 tabletter. 
EU/1/03/258/013, 56 tablets, component of a 112 tablet multipack.
• hævet og kløende udslæt (nældefeber) 
• raised and itchy rash (hives)
MARKEDSFØRINGSTILLADELSESNUMMER (NUMRE) EU/1/03/258/014, 56 tabletter, del af multipakning med 112 tabletter. 
EU/1/03/258/014, 56 tablets, component of a 112 tablet multipack.
Hudreaktioner (for eksempel nældefeber, kløe, udslæt) 
Very rare skin reactions (e.g. urticaria, pruritis, rash)
Avandamet 1 mg/500 mg tabletter er gule og mærket ”gsk” på den ene side og ”1/500” på den anden. 
What Avandamet looks like and contents of the pack Avandamet 1 mg/500 mg tablets are yellow and marked "gsk" on one side and "1/500" on the other.
Hvis du har glemt at tage Avandamet 
BEFORE YOU TAKE AVANDAMET
Hjerteiskæmi3* 
cardiac ischaemia3*
• knoglebrud 
• dizziness
Data fra kliniske undersøgelser og post-marketingdata I Tabel 3 er bivirkninger listet under organklasser og absolutte frekvenser. 
Table 3 presents adverse reactions by system organ class and by frequency category.
AVANDAMET 4 mg/1000 mg filmovertrukne tabletter rosiglitazon/metformin HCl 
NAME OF THE MEDICINAL PRODUCT AVANDAMET 4 mg/1000 mg film-coated tablets rosiglitazone/metformin HCl
MF (EU)nummer 
MA (EU) number
1 hætteglas + 1 injektionssprøjte + 1 kanyle + 1 adaptor + 2 spritservietter 
1 vial + 1 syringe + 1 needle + 1 adaptor + 2 alcohol pads
40 mg/0,8 ml 
EU/1/19/1356/001 IDACIO 40 mg/0.8 ml
(Særnavn) navn Styrke Lægemiddelform Administration Emballage 
Strength Pharmaceutical Form
Injektionsvæske, opløsning 
Solution for injection
Fyldt injektionssprøjte (glas) 
Subcutaneous use vial (glass)
MF (EU)-nummer (Særnavn) Navn Styrke 
MA (EU) number (Invented) name
Lægemiddelform Administration Emballage Paknings-størrelse 
Pharmaceutical Form
Dette sammendrag blev senest ajourført i 07-2015. 
This summary was last updated in 07-2015.
Patienten falder derfor i søvn og vågner på usædvanlige tidspunkter. 
As a result, patients fall asleep and wake up at unusual times.
Det kræver imidlertid vedvarende behandling at opretholde de gavnlige virkninger. 
However, continued treatment would be necessary to maintain the beneficial effects.
Europa-Kommissionen udstedte en markedsføringstilladelse med gyldighed i hele Den Europæiske Union for Hetlioz den 3. juli 2015. 
The European Commission granted a marketing authorisation valid throughout the European Union for Hetlioz on 3 July 2015.
Lægemidlet skal tages uden samtidig fødeindtagelse. 
The medicine should be taken without food.
Dette dokument er et sammendrag af den europæiske offentlige vurderingsrapport (EPAR) for Hetlioz. 
This is a summary of the European public assessment report (EPAR) for Hetlioz.
Agenturets Udvalg for Lægemidler til Mennesker (CHMP) konkluderede, at fordelene ved Hetlioz opvejer risiciene, og anbefalede, at det godkendes til anvendelse i EU. 
The Agency's Committee for Medicinal Products for Human Use (CHMP) decided that Hetlioz's benefits are greater than its risks and recommended that it be approved for use in the EU.
Disse bivirkninger er sædvanligvis lette eller moderate og er forbigående. 
These are usually mild or moderate in severity and temporary.
Hetlioz er beregnet til langtidsbehandling. 
Hetlioz is intended for long-term use.
Andre oplysninger om Hetlioz 
Other information about Hetlioz
Den anbefalede dosis er 1 kapsel dagligt, der tages én time før sengetid på samme klokkeslæt hver aften. 
The recommended dose is one capsule per day, taken one hour before bedtime, at the same time every night.
I den anden undersøgelse fik 57 patienter først Hetlioz i omkring 11 uger. 
In the second study, 57 patients first received Hetlioz for around 11 weeks.
Der er udarbejdet en risikostyringsplan for at sikre, at Hetlioz anvendes så sikkert som muligt. 
A risk management plan has been developed to ensure that Hetlioz is used as safely as possible.
De hyppigste bivirkninger ved Hetlioz (som kan forekomme hos mere end 3 ud af 100 personer), er hovedpine, søvnighed, kvalme og svimmelhed. 
The most common side effects with Hetlioz (which may affect more than 3 in 100 people) are headache, somnolence, nausea (feeling sick) and dizziness.
Hvad sikkerheden angår, blev Hetlioz påvist at tåles godt og kun at medføre få lette bivirkninger. 
Regarding safety, Hetlioz was shown to be well tolerated, causing only few mild side effects.
Hetlioz indeholder det aktive stof tasimelteon. 
Hetlioz contains the active substance tasimelteon.
Hvilke foranstaltninger træffes der for at sikre risikofri og effektiv anvendelse af Hetlioz? 
What measures are being taken to ensure the safe and effective use of Hetlioz?
CHMP bemærkede, at kun ca. 20 % af patienterne ville kunne få gavn af behandlingen med Hetlioz, men i betragtning af, at der ikke findes godkendte behandlinger af non-24-hour sleep-wake disorder, og at det er en invaliderende sygdom, blev dette beskedne resultat alligevel anset for vigtigt. 
The CHMP noted that only around 20% of patients would be able to benefit from treatment with Hetlioz, but in view of the lack of approved treatments for non-24-hour sleep-wake disorder, which is a debilitating condition, this modest response was still considered important.
På baggrund af denne er der anført sikkerhedsoplysninger i produktresuméet og indlægssedlen for Hetlioz, herunder passende forholdsregler, som sundhedspersonale og patienter skal følge. 
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Hetlioz, including the appropriate precautions to be followed by healthcare professionals and patients.
Hvad er Hetlioz, og hvad anvendes det til? 
What is Hetlioz and what is it used for?
Den fuldstændige EPAR og resuméet af risikostyringsplanen for Hetlioz findes på agenturets websted under: ema.europa.eu/Find medicine/Human medicines/European public assessment reports. 
The full EPAR and risk management plan summary for Hetlioz can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Da antallet af patienter med non-24-hour sleep-wake disorder er lavt, betragtes sygdommen som "sjælden", og Hetlioz blev udpeget som "lægemiddel til sjældne sygdomme" den 23. februar 2011. 
Because the number of patients with non-24-hour sleep-wake disorder is low, the disease is considered ‘rare', and Hetlioz was designated an ‘orphan medicine' (a medicine used in rare diseases) on 23 February 2011.
Sammendraget af udtalelsen fra Udvalget for Lægemidler til Sjældne Sygdomme om Hetlioz findes på agenturets websted under: ema.europa.eu/Find medicine/Human medicines/Rare disease designation. 
The summary of the opinion of the Committee for Orphan Medicinal Products for Hetlioz can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
Det aktive stof i Hetlioz, tasimelteon, virker på de samme receptorer som melatonin og fremkalder derved søvn, så søvnmønsteret reguleres. 
The active substance in Hetlioz, tasimelteon, acts on the same receptors as melatonin to promote sleep and regulate sleep patterns.
Hetlioz fås som kapsler (20 mg) og udleveres kun på recept. 
Hetlioz is available as 20 mg capsules and can only be obtained with a prescription.
Det er ikke en praktisk vejledning i, hvordan Hetlioz bør anvendes. 
It is not intended to provide practical advice on how to use Hetlioz.
Hvorfor blev Hetlioz godkendt? 
Why is Hetlioz approved?
Hvis du ønsker yderligere oplysninger om behandling med Hetlioz, kan du læse indlægssedlen (også en del af denne EPAR) eller kontakte din læge eller dit apotek. 
For more information about treatment with Hetlioz, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Den fuldstændige liste over bivirkninger og begrænsninger med Hetlioz fremgår af indlægssedlen. 
For the full list of all side effects and restrictions with Hetlioz, see the package leaflet.
Sygdommen non-24-hour sleep-wake disorder optræder næsten udelukkende hos helt blinde personer, idet patientens søvnmønster ikke er synkroniseret med dag og nat, men ofte følger en rytme, der er længere end den normale 24-timers døgnrytme. 
Non-24hour sleep-wake disorder is a condition that occurs almost exclusively in people who are completely blind, where patients have sleep patterns that are not synchronised with day and night and often follow a cycle that is longer than the standard 24-hour clock.
Når lægemidlet tages på et passende klokkeslæt hver dag, kan det medvirke til at omstille kroppens søvnrytme til et mere normalt mønster. 
By taking it at a suitable time each day it can help to reset the sleep-wake cycle to more standard timing.
Hvilke risici er der forbundet med Hetlioz? 
What are the risks associated with Hetlioz?
Af de 10 patienter, der stadig fik Hetlioz, var 9 stadig tilpasset til 24-timers klokkeslættet i slutningen af undersøgelsen, sammenholdt med 2 ud af de 10 patienter, der skiftede til placebo. 
Of the 10 patients who remained on Hetlioz, 9 people remained adjusted to 24-hour clock at the end of the study, compared with 2 of the 10 patients who were switched to placebo.
Hormonet melatonin spiller en vigtig rolle i reguleringen af kroppens søvnrytme. 
A hormone called melatonin plays a key role in co-ordinating the body's sleep-wake cycle.
Hvis du ønsker praktisk vejledning om anvendelsen af Hetlioz, kan du læse indlægssedlen eller kontakte din læge eller dit apotek. 
For practical information about using Hetlioz, patients should read the package leaflet or contact their doctor or pharmacist.
Hvordan anvendes Hetlioz? 
How is Hetlioz used?
Efter en måneds behandling var 20 % af de patienter, der fik Hetlioz (8 ud af 40) i stand til at tilpasse sig 24-timers klokkeslættet, sammenholdt med ca. 3 % af dem, der fik placebo (1 ud af 38). 
20% of patients who received Hetlioz (8 out of 40) were able to adjust to the 24-hour clock after 1 months of treatment, compared with around 3% of patients on placebo (1 out of 38).
To hovedundersøgelser har vist, Hetlioz er effektivt til at hjælpe patienten med at omstille sig til den normale 24-timers døgnrytme. 
Hetlioz has been shown to be effective at helping patients adjust to the standard 24-hour clock in 2 main studies.
Hetlioz er et lægemiddel til behandling af søvnforstyrrelsen "non-24-hour sleep-wake disorder" hos voksne, der er totalt blinde. 
Hetlioz is a medicine used to treat totally blind adults with non-24-hour sleep-wake disorder.
Hvilke fordele viser undersøgelserne, at der er ved Hetlioz? 
What benefits of Hetlioz have been shown in studies?
Personer med normal opfattelse af lys og mørke danner melatonin, når det er mørkt. 
In people with normal perception of light and dark, melatonin is produced in hours of darkness and promotes sleep by acting on melatonin receptors in specific areas of the brain.
De patienter, der kunne omstille sig til 24-timers klokkeslættet (i alt 20 patienter), fik derefter i yderligere otte uger enten Hetlioz eller placebo. 
Those patients who were able to adjust to the 24-hour clock (20 patients in total) were then given Hetlioz or placebo for a further 8 weeks to study how well the effect of Hetlioz was maintained.
Det vigtigste mål for virkningen var den procentdel af patienterne, der var i stand til at tilpasse sig til 24-timers døgnrytmen. 
The main measure of effectiveness was the percentage of patients who were able to adjust to the 24-hour clock, which was calculated by looking at how the amount of melatonin breakdown products changed in the patient's urine over time.
I den første undersøgelse deltog i alt 84 totalt blinde patienter med non-24-hour sleep-wake disorder. 
The first study, which involved a total of 84 totally blind patients with non-24-hour sleep-wake disorder, compared Hetlioz with placebo (a dummy treatment).
Efter syv måneders behandling var resultaterne bedre hos en undergruppe af patienterne. 
Improved results were seen in a subset of patients after 7 months of treatment, which indicate that patients may take weeks or months to respond.
Hvordan virker Hetlioz? 
How does Hetlioz work?
Det må heller ikke anvendes til følgende grupper: 
It must also not be used in the following groups:
Dette sammendrag blev sidst ajourført i 01-2012. 
This summary was last updated in 01-2012.
Det primære effektmål var, hvor længe patienterne levede. 
The main measure of effectiveness was how long the patients lived.
Europa-Kommissionen udstedte en markedsføringstilladelse med gyldighed i hele Den Europæiske Union for Teysuno den 14 marts 2011. 
The European Commission granted a marketing authorisation valid throughout the European Union for Teysuno on 14 March 2011.
Den anbefalede dosis for et behandlingsforløb er 25 mg/m2 to gange om dagen (om morgenen og om aftenen) i tre uger, efterfulgt af en hvileperiode på en uge. 
The recommended dose for one cycle of treatment is 25 mg/m2 twice a day (in the morning and evening) for three weeks, followed by a one-week rest period.
Teysuno-kapsler indtages sammen med vand mindst en time før eller efter et måltid. 
Teysuno capsules are taken with water at least one hour before or after a meal.
Derved forhindrer det væksten af cancercellerne, der til sidst dør. 
As a result, it prevents the growth of cancer cells and eventually kills them.
Begge lægemidler blev givet med cisplatin. 
Both medicines were given with cisplatin.
• gravide eller ammende kvinder 
• pregnant or breast-feeding women;
• patienter, der ikke må modtage cisplatin. 
• patients who should not be receiving cisplatin.
Den fuldstændige EPAR for Teysuno findes på EMA's websted: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports. 
The full EPAR for Teysuno can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Dette dokument er et sammendrag af den europæiske offentlige vurderingsrapport (EPAR) for Teysuno. 
This is a summary of the European public assessment report (EPAR) for Teysuno.
Andre oplysninger om Teysuno 
Other information about Teysuno
Forløbet gentages hver fjerde uge, også når cisplatinbehandlingen stoppes efter seks forløb. 
The cycle is repeated every four weeks, including once cisplatin administration is stopped after six cycles.
Det forklarer, hvordan Udvalget for Lægemidler til Mennesker (CHMP) vurderede lægemidlet og nåede frem til sin udtalelse til fordel for udstedelse af en markedsføringstilladelse og til sine anbefalinger om anvendelsesbetingelserne for Teysuno. 
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Teysuno.
• patienter med mangel på enzymet dihydropyrimidin dehydrogenase (DPD) og patienter, der inden for de seneste fire uger er blevet behandlet med et lægemiddel, som hæmmer dette enzym 
• patients with a deficiency of the enzyme dihydropyrimidine dehydrogenase (DPD) as well as patients who, within the previous four weeks, have been treated with a medicine that inhibits this enzyme;
Det anvendes i kombination med cisplatin (et andet lægemiddel mod cancer). 
It is used in combination with cisplatin (another anticancer medicine).
Teysuno må ikke anvendes til personer, som er overfølsomme (allergiske) over for nogen af de aktive stoffer eller et eller flere af de øvrige indholdsstoffer. 
Teysuno must not be used in people who are hypersensitive (allergic) to any of the active substances or any of the other ingredients.
Dosen, der skal tages, beregnes på basis af det aktive stof tegafur og patientens legemsoverfladeareal (beregnet ved hjælp af patientens højde og vægt). 
The dose to be taken is calculated based on the active substance tegafur and the patient's body surface area (calculated using the patient's height and weight).
CHMP konkluderede, at fordelene ved Teysuno er større end risiciene, og anbefalede udstedelse af markedsføringstilladelse for Teysuno. 
The CHMP decided that Teysuno's benefits are greater than its risks and recommended that it be given marketing authorisation.
Tegafur er et ”prodrug”, der omdannes i kroppen til et kemikalie, som hedder 5-fluorouracil (5-FU). 
Tegafur is a ‘prodrug' that is converted in the body to a chemical called 5-fluorouracil (5-FU).
Det findes som kapsler, der indeholder 15 mg tegafur med 4,35 mg gimeracil og 11,8 mg oteracil, og som kapsler, der indeholder 20 mg tegafur med 5,8 mg gimeracil og 15,8 mg oteracil. 
It is available as capsules containing 15 mg tegafur with 4.35 mg gimeracil and 11.8 mg oteracil, and as capsules containing 20 mg tegafur with 5.8 mg gimeracil and 15.8 mg oteracil.
Teysuno er et lægemiddel, der indeholder de aktive stoffer tegafur, gimeracil og oteracil. 
Teysuno is a medicine that contains the active substances tegafur, gimeracil and oteracil.
Behandling med Teysuno-kapsler var lige så effektiv som behandling med 5-FU-infusioner. 
Treatment with Teysuno capsules was as effective as treatment with 5-FU infusions.
De patienter, der modtog Teysuno med cisplatin, overlevede i gennemsnit i 8,6 måneder sammenlignet med 7,9 måneder for de patienter, der modtog 5-FU med cisplatin. 
Patients receiving Teysuno with cisplatin lived for an average of 8.6 months compared with 7.9 months for patients receiving 5-FU with cisplatin.
Teysuno må kun ordineres af en kvalificeret læge med erfaring i behandling af cancerpatienter med lægemidler mod cancer. 
Teysuno should only be prescribed by a qualified doctor experienced in treating cancer patients with anticancer medicines.